|
Activities, Bill Numbers and Titles
|
|
H3734: An Act relative to the substitution of interchangeable biosimilars
|
Support
|
N/A
| Sanofi US |
$431.60
|
|
H2646: An Act to eliminate the tax deduction for direct to consumer pharmaceutical marketing
|
Oppose
|
N/A
| Sanofi US |
$258.95
|
| | | | Total amount |
$690.55
|
|
|
|
|
|
|
Meals, Travel, and Entertainment Expenses
|
| No meals, travel, or entertainment expenses were filed for this disclosure reporting period. |
|
| |
|
Additional Expenses
|
| No additional expenses were filed for this disclosure reporting period. |
|
| |
|
Campaign Contributions
|
| No campaign contributions were filed for this disclosure reporting period. |
|